Protein ubiquitination by E3 ubiquitin ligases plays an important role in cancer development. In this study, we provide experimental evidence that a RING-finger-containing protein RNF13 is an ER/Golgi membrane-associated E3 ubiquitin ligase and its RING finger domain is required for the ubiquitin ligase activity. Immunohistochemical analysis of pancreatic ductal adenocarcinoma (PDAC) and paracancerous normal tissues from 72 patients documented RNF13 over-expression in 30 tumor samples (41.7%, 30/72), and its expression was significantly associated with histological grading (P = 0.024). In addition, RNF13 was detected in precancerous lesions: tubular complexes in chronic pancreatitis (CP) and pancreatic intraepithelial neoplasia (PanIN) (79.3%, 23/29 and 62.8%, 22/35, respectively). Moreover, RNF13 staining was significantly correlated with Tenascin-C expression (P = 0.004) in PDAC samples, further supporting the role of RNF13 in cancer progression. Over-expression of wild type but not RING domain-mutant RNF13 in pancreatic MiaPaca-2 cancer cells increased invasive potential and gelatinolytic activity by matrix metalloproteinase-9. Taken together, these findings reveal that RNF13 is a novel E3 ubiquitin ligase involved in pancreatic carcinogenesis; ubiquitin-mediated modification of proteins by RNF13 may participate in pancreatic cancer development.
Introduction
Many RING-finger-containing monomeric proteins and multi-subunit complexes possess ubiquitin ligase activity and play a crucial role in degradation and trafficking of regulatory proteins; several have been reported to be involved in tumorigenesis and cancer metastasis [1] . For example, RNF11 enhances transforming growth factor-β signaling and suppresses the progression of breast cancer by binding and degrading Smurf2 [2, 3] . Breast cancer-associated gene 2 (BCA2) is an E3 with a RING domain that is over-expressed in invasive breast cancer and positively correlates with estrogen receptor expression and survival, but negatively with lymph node metastasis [4] . Recently ubiquitin ligase SCF-β-TrCP1 has been shown to be a critical determinant for Smad4 protein degradation in pancreatic cancer cells, and the somatic homozygous H460R mutation in FBXW7, a subunit of an SCF-type ubiquitin ligase complex associated with Cyclin E over-expression, was observed in a subset of pancreatic cancers [5, 6] . A hallmark of pancreatic cancer is its extensive local invasion and early systemic dissemination. The vast majority of pancreatic cancer patients present with advanced and incurable disease [7] . Therefore, identification and characterization of novel genes involved in pancreatic cancer development from precancerous lesions, such as pancreatic intraepithelial neoplasia (PanIN), would be a logical requirement for the prevention and effective treatment of pancreatic cancer [8] .
RNF13 or C-RZF (GenBank accession number NM_ 205355.1) was initially identified in chicken embryo brain by way of its expression being stimulated by the substrate adhesion molecule Cytotactin/Tenascin-C [9] . The latter is up-regulated in acute and chronic pancreatitis (CP), PanINs www.cell-research.com | Cell Research Qiang Zhang et al. 349 npg and pancreatic cancer, and the increased expression of Tenascin-C is correlated with pancreatic cancer differentiation [10] . Expression level, splicing variants and distribution of Tenascin-C were also found to be associated with the progression of several cancers, especially breast cancer and brain tumors [11] [12] [13] . In addition, the human RNF13 gene (GenBank accession number NM_007282.1) is localized at chromosome 3q25.1, a site suggested to harbor genes involved in pancreatic cancer development [14] . Therefore, it is conceivable to investigate the potential role of RNF13 in the pathogenesis of human pancreatic cancer.
In the present study, we provide experimental evidence that RNF13 is a trans-membrane RING-type E3 ubiquitin ligase highly expressed in pancreatic ductal adenocarcinoma (PDAC) and precancerous lesions. A significant association between RNF13 expression and histological grade of PDAC or the expression of Tenascin-C was also observed. Finally, ubiquitin ligase activity of RNF13 was found to be involved in pancreatic cancer cell invasive potential in vitro.
Results

RNF13 encodes a membrane glycoprotein associated with ER/Golgi
The RNF13 gene is located on human chromosome 3q25.1 and encodes a protein product of 381 amino acids. The RNF13 protein (NP_009213.1) contains several predicted functional domains, including a protease-associated (PA) domain, a RING-H2 type RING finger domain, a signal peptide (SP), a nuclear localization signal (NLS) and a transmembrane (TM) region ( Figure 1A ). These features suggest that RNF13 is a member of GRAIL (Gene Related to Anergy in Lymphocytes) paralogs, which are characterized by PA-TM-RING domains [15] . Analysis of RNF13 expression in multiple human tissues by Western blotting showed that RNF13 is expressed as a 60 kDa protein ( Figure 1B) . The sub-cellular localization of RNF13 was determined in MiaPaca-2 pancreatic cancer cells transfected with the Myc-tagged RNF13 expression vector. Figure 1C shows that the RNF13 protein is predominantly localized in the cytoplasm and co-localizes with the ER protein Bip/GRP78 and Golgi antigen, but not with the early endosome resident EEA1; this behavior is similar to that of other members of the GRAIL family, such as GRAIL and RING105 [16, 17] . Furthermore, RNF13 was found to be enriched in the nonionic detergent Triton X-114 phase, supporting its association with membranes ( Figure 1D ). Pretreatment of RNF13-transfected cells with tunicamycin (an N-glycosylation inhibitor) and extraction of total cellular proteins with N-glycosidase F demonstrated a mobility shift of the RNF13 protein from 60 to 50 kDa Figure 1E ), suggesting that RNF13 is an N-glycosylated protein.
To identify the N-glycosylated sites in RNF13 protein, two mutants (RNF13 N43A and N88A) were created at two predicted glycosylation sites (N43 and N88). RNF13 N88A displayed a lower molecular weight, whereas the RNF13 N43A mutant shifted together with wild-type RNF13 ( Figure 1F ). These results suggest that RNF13 is glycosylated at N88.
RNF13 is a novel E3 ubiquitin ligase
Sequence alignment analysis showed that the RING finger domain of RNF13 shares significant homology with several known E3 ligases (Figure 2A ), suggesting that RNF13 could be an E3 ubiquitin ligase. To test this possibility we performed an auto-ubiquitination assay, which is a specific test for demonstration of a RING-finger-domain-containing E3 ubiquitin ligase [18, 19] . Recombinant RNF13 (207-374) containing the entire RING domain exhibited ubiquitin ligase activity. This was activated by UbcH5a and UbcH5c in an ATP-and E1-dependent manner ( Figure 2B ); all components were required for the polyubiquitination of RNF13 ( Figure 2C ). To further confirm npg the requirement for the RING finger domain for RNF13 ubiquitin ligase activity, we carried out the ubiquitination assay with the wild-type RNF13 and two RNF13 RING finger mutants, C258A/H260A and W270A. As indicated in Figure 2D , both mutants almost completely lost their E3 ubiquitin ligase activity. In addition, we observed that RNF13 exerted E3 ubiquitin ligase activity in vivo, especially in the presence of the proteasome inhibitor MG-132.
As indicated in Figure 2E , one of the RNF13 RING finger domain mutants, C258A/H260A, completely lost its E3 ligase activity while the other mutant W270A maintained little E3 ligase activity. In summary, these data confirm that RNF13 is a bona fide RING-type E3 ubiquitin ligase.
RNF13 expression is associated with histological grading in patients with PDAC
It has been reported that RNF13 expression is up-regulated by the cancer-related extracellular protein Tenascin-C [9] ; this prompted the study of RNF13 role in cancer development through the analysis of its expression pattern in 72 PDAC patients. RNF13 expression was analyzed by immunohistochemistry with the commercially available anti-RNF13 polyclonal antibody (Abcam 4288). We first tested the sensitivity and specificity of the antibody (Supplementary information, Figure S1 ). Then RNF13 protein expression was examined in normal pancreas tissue; the results indicated that RNF13 is detectable only in islets but not in pancreatic ducts and acini ( Figure 3A and 3G). Interestingly, RNF13 was found to be expressed in pancreatic ducts and acini in PDAC samples, suggesting that RNF13 expression is likely associated with pancreatic cancer development. To further verify this association, RNF13 expression was examined in samples from the 72 PDAC patients; intensity of staining was scored as de- Figure 3G ). Collectively, these results indicate that the E3 ubiquitin ligase RNF13 is over-expressed in human PDAC.
To determine whether RNF13 expression is correlated with clinico-pathological parameters, the relationship between RNF13 expression, histological grading and clinical stage was analyzed in the 72 PDAC patients. We found that elevated expression of RNF13 was significantly correlated with histological grading (P = 0.024) but not with pathologic stage, lymph node metastasis and depth of invasion (Table 1 ). Positive staining of RNF13 was observed predominantly in well-differentiated tumors (G1, 17/29), while negative staining of RNF13 was found in poorlydifferentiated tumors (G3, 18/23), suggesting that RNF13 expression is associated with well-differentiated PDAC.
RNF13 is expressed in the tubular complexes in CP and PanIN
We then investigated the role of RNF13 in early-stage pancreatic cancer by analyzing RNF13 expression in precancerous lesions including tubular complexes in CP and PanIN. In CP adjacent to PDAC, 23 out of 29 (79.3%) samples exhibited positive staining of RNF13 in tubular 
RNF13 and Tenascin-C are co-expressed in PDAC
RNF13 expression is up-regulated by Tenascin-C [9] , an extracellular matrix glycoprotein that has been proposed as a tumor marker with prognostic significance in many human cancers [20] . This prompted us to investigate a Table 2) . Figure 6A ). The cell proliferation assay indicated that there was no significant difference in growth rates and cell viability among the three groups ( Figure 6B ). We next examined whether RNF13 could affect the invasive potential of pancreatic cancer cells by Matrigel invasion assay; MiaPaca-2 cells overexpressing wild-type RNF13 exhibited enhanced invasive ability, whereas the ubiquitin ligase-deficient RNF13 mutant failed to promote cell invasion ( Figure 6C ). To test whether RNF13 expression in MiaPaca-2 cells affects the activity of matrix metalloproteases, key enzymes for degradation of extracellular matrix, we performed a gelatin zymography assay; increased MMP-9 (gelatinase B) activity was only detected in cells carrying the wild-type RNF13, but not in those expressing the RNF13 RING mutant or control vector. However, all cell lines from the three groups exhibited similar MMP-2 (gelatinase A) activity ( Figure 6D and 6E) . Hence, our data demonstrated that RNF13 might play a functional role in enhancing pancreatic cancer cell invasion in vitro by promoting metalloprotease function.
RNF13 promotes invasion in pancreatic cancer cells
Based on the above observations, we then investigated possible molecular functions of RNF13 in pancreatic cancer cells. Cell proliferation and invasion were examined in the MiaPaca-2 pancreatic cancer cell line, which stably over-expresses either wild-type RNF13 (MiaP2-RNF13 WT No. 4, and No. 6) or RNF13 RING domain mutant C258A/H260A (MiaP2-RNF13 Mt. No. 1 and No. 2), and two mock-transfected clones (MiaP2-Vec1 and MiaP2-Vec2) (
Discussion
RNF13 was initially identified as a Tenascin-C-stimulated factor; at the same time, elevated Tenascin-C expression was observed in precancerous lesions and correlated with differentiation of PDAC [9, 10, 21] . Thus, we investigated the pathologic/clinical relevance of RNF13 expression in PDAC; this study indicates that RNF13 is a novel tumorassociated E3 ubiquitin ligase that may indeed play a role in the early phase of PDAC. RNF13 was over-expressed in PDAC samples from individual patients and in an independent set of samples from archival tissue microarray compared to normal tissues. Furthermore, RNF13 expression correlated significantly with expression of the cancer-related Tenascin-C in the same PDAC samples, and over-expression of RNF13 in pancreatic cancer cells enhanced invasiveness and MMP-9 activity. Finally, microarray analysis of RNF13 expression also demonstrated higher level of RNF13 mRNA in some basal cell carcinoma, epithelial ovarian carcinoma and melanoma (personal communication from Francesco M Marincola, Department of Transfusion Medicine, NIH).
RNF13 contains an N-terminal PA domain and a Cterminal RING finger domain, which is characteristic of GRAIL paralogs [15] . The PA domain, a motif found in plant vacuolar sorting proteins, transferrin receptor and different protease superfamilies, could serve as a proteininteracting domain [22, 23] . The RING finger domain, a unique feature of RING-type E3 ubiquitin ligase, plays an important role in ubiquitin-mediated protein modification by mediating the direct transfer of E2-bound ubiquitin to substrates without thioester bond formation [24] . We have shown that RNF13 is a RING-type ubiquitin ligase and that the RING finger domain of RNF13 is necessary and sufficient for its ability to catalyze ubiquitination. Like most RING E3 ligases showing short half-life because of auto-ubiquitination, the stability of wild-type but not RING mutant RNF13 is regulated by the proteasome (data not shown). Under normal circumstances, the protein level npg of RNF13 may be strictly regulated by its expression, auto-ubiquitination and specific ubiquitin protease, which may be crucial for the maintenance of cell homeostasis. Dysfunction of E3 ubiquitin ligases is implicated in cancer development, because of their central role in promoting the ubiquitination of proteins that are essential for a variety of cellular functions. Many RING-type E3 ligases could be oncoproteins or tumor suppressors because their deregulation has been shown to be associated with human carcinogenesis. For instance, the G allele of MDM2 promoter 309T/G polymorphism, which is associated with higher MDM2 mRNA and protein levels, leads to a 2-to 3-fold increased risk of developing pancreatic cancer and to a worse prognosis in patients who develop the disease [25] . In this study, we observed that elevated expression of RNF13 in PDAC samples was significantly correlated with histological grading (P = 0.024) and often detected in welldifferentiated samples (17/29), providing additional new information supporting a functional role of E3 ubiquitin ligases in pancreatic cancer development. RNF13 expression was associated with the expression of Tenascin-C in PDAC (P = 0.004; OR, 4.67), suggesting that RNF13 may participate coordinately with Tenascin-C in mediating carcinogenesis. Although in the 72 PDAC samples examined here the ratio of Tenascin-C positive staining was lower than reported by others, co-expression of RNF13 and Tenascin-C supports their combined role in cancer development [10] . Stromal cells such as carcinomaassociated fibroblasts (CAFs) can secrete Tenascin-C, which stimulates Wnt/β-catenin, MAP kinase and EGFR signaling at different stages of cancer development in different cancer cell types [26, 27] . RNF13 may participate in Tenascin-C-mediated signaling and possibly it might mediate the function of Tenascin-C. The observation that RNF13 is highly expressed in precancerous lesions such as PanINs (62.8%) and in tubular complexes (79.3%) in CP is of further significance. Detection and treatment of early, non-invasive PanIN can have a major impact on pancreatic cancer survival. PanINs arise in the smaller pancreatic ducts and are classified morphologically into three grades, according to nuclear polarity, nuclear size (pleomorphism) and hyper-chromatic staining [28] . Despite complex interactions between tumor cells and PanINs, histological and molecular evidence suggests that PanINs can gradually progress to PDACbearing genetic traits such as K-ras mutation, Cyclin D1 over-expression and loss of p16 expression [29, 30] . Since CP is also an independent risk factor for the development of PDAC [31] , the high proportion of RNF13 expression in CP and PanINs suggests that RNF13 might be involved in the earliest stages of pathogenesis of PDAC and could potentially be used as a biomarker for diagnosis of PDAC at a non-invasive stage.
As shown in Figure 1C , RNF13 is localized in the membrane of ER and Golgi, indicating that RNF13 is likely a type I TM protein: the N-terminal PA domain would be internal toward the lumen and the C terminus RING finger domain would face the cytosol. The integral membrane localization of RNF13 implicates that both the cytoplasmic and membrane-associated proteins could be ubiquitinated by RNF13. The ectopic expression of RNF13 in transformed pancreatic cancer cells increased the activity of extra-cellular MMP-9 (gelatinase B) that contains a fibronectin-like sequence and plays a critical role in tumor invasion and metastasis [32] . In view of the ability of wild-type but not RING mutant RNF13 to function as an E3 ligase and promote pancreatic cancer cell invasion, our results suggest that the increase of MMP-9 activity is likely due to protein ubiquitination by RNF13. The increased invasive activity of RNF13 transfectants suggests that RNF13 might play a functional role in the later stages of cancer development in vivo. In addition, our data derived from the study of patients with PDAC demonstrated high frequency of RNF13 expression in precancerous lesions and an association with well-differentiated tumors, pointing to the possibility that RNF13 might stimulate proliferation and enhance tumorigenesis. Taken together, our findings imply that RNF13, as an E3 ubiquitin ligase, might mediate pancreatic cancer initiation, progression and invasion at multiple stages through ubiquitination and consequent modification of various substrates. Therefore, further identification of RNF13-mediated ubiquitination substrate(s) and characterization of its role in mediating the actions of Tenascin-C and other extracellular matrix proteins will not only shed light on the molecular mechanism of RNF13 function in cancer development but also provide a molecular basis for the use of RNF13 as a diagnostic and therapeutic target in cancer.
Materials and Methods
Cell lines and antibodies
MiaPaca-2, COS-7 cells were obtained from the American Type Culture Collection. Anti-human RNF13 antibody was purchased from Abcam (abcam 4288) (Abcam Company Research, UK). The monoclonal antibody anti-Tenascin-C (clone BC-24) and HA antibody were obtained from Sigma (St. Louis, MO). The endoplasmic reticulum protein BiP/GRP78 antibody and the early endosome protein EEA1 antibody were from BD transduction Laboratories (Palo Alto, CA). The anti-Golgi Apparatus mAb (AE-6) was from Calbiochem (LaJolla, CA). The anti-Ubiquitin (P4D1), anti-Myc (9E10), anti-β-Actin and anti-β-Tubulin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Expression vector construction and stable cell lines establishment
RNF13 cDNA was cloned into the pcDNA4.0-Myc-His vector with the forward primer 5′-CCC AAG CTT ATG CTG CTC TCC ATA GGG ATG CTC A-3′ and the reverse primer 5′-CCG CTC GGA ACA GTA TTT GCT ATG TTG TAA TCC-3′. For generating C258A/H260A mutant the internal primers 5′-AGA ATC CTT CCC TGT TCC CAT GCT TAT CAT T-3′ and 5′-GCA ATG ATA AGC ATG GGA ACA GGG AAG GAT-3′ were used, and for W270A mutant the internal primers were 5′-GGT TTT AGT TAG CCA AGG GTC TAC ACA CTT GCA AT-3′ and 5′-GCA AGT GTG TAG ACC CTT GGC TAA CTA AAA CCA A-3′, respectively. The nucleotide sequence encoding the HA epitope was introduced into 3′ of human RNF13 cDNA ORF (wild-type and RING domain mutant C258A/H260A) for constructing the pEAK13 expression vector. N43A (primers: 5′-GCA TAT AAC TTT GAA GCT GCA TCT CAG AC-3′ and 5′-GTC TGA GAT GCA GCT TCA AAG TTA TAT GC-3′) and N88A (primers: 5′-TCC ACC AGT AAA AGA CGC TTC ATC TGG CAC-3′ and 5′-GTG CCA GAT GAA GCG TCT TTT ACT GGT GGA-3′) mutants were cloned into pEAK13 as the strategy of RING mutants. Stable transformants (MiaP2-vector, MiaP2-RNF13 WT and MiaP2-RNF13 Mutant) were developed by cloning the colonies under selection with 800 μg/mL G418 (Sigma-Aldrich, St Louis, MO).
In vitro and in vivo ubiquitination assay
One microgram purified His-RNF13 (207-374) recombinant protein was incubated for 1 h at 30 ºC in a 10 µL reaction mixture, consisted of 100 nM E1 (ubiquitin activating enzyme, Sigma-Aldrich), 1 µM each E2 (ubiquitin conjugating enzyme set containing UbcH2, UbcH3, UbcH5a, UbcH5b, UbcH5c, UbcH6, UbcH7, and UbcH10 from Calbiochem), 5 µM ubiquitin (Sigma-Aldrich), 50 mM Tris-HCl (pH 7.5), 2 mM ATP, 2.5 mM MgCl 2 and 1 mM DTT. The reaction was stopped by adding 10 µL 2×SDS loading buffer. The boiled samples were separated on 8% SDS-PAGE and immuneblotted with the anti-ubiquitin antibody (P4D1).
Ubiquitination assay of wild-type (WT) Myc-RNF13 and its two npg mutants (C258A/H260A and W270A) expressed in COS-7 cells was performed as described [33] . In brief, immune precipitates from the transfected cells were incubated with 5 µM ubiquitin, 100 nM E1, 1 µM UbcH5a in 50 mM Tris buffer (pH 7.5) containing 2 mM ATP, 2.5 mM MgCl 2 and 1 mM DTT for 1 h at 30 ºC. The mixtures were separated on 8% SDS-PAGE and immune-blotted with antiubiquitin antibody. For the in vivo ubiquitination assay, COS-7 cells were transiently co-transfected with either 10 µg of Myc-RNF13 (WT) or its mutants (C258A/H260A, W270A) and 5 µg HA-ubiquitin, respectively. As controls, cells were transfected by 10 µg of vector DNA and 5 µg HA-ubiquitin. After 24 h, the cells were treated with 10 mM MG-132 for 4 h. The clarified cell lysates were immune precipitated with anti-Myc antibody and protein A/G plus agarose and washed with lysis buffer with MG-132 and protease inhibitor cocktail. Samples were separated by 8% SDS-PAGE and immune-blotted with anti-HA antibody.
Patients and specimens
Human tissue samples were used according to the guidelines of the Ethical Committee of the Peking Union Medical College Hospital. Surgically resected specimens from 72 patients (age range, 29-78 years) with PDAC were examined. The patient population represents a randomly selected subgroup from a clinical series that includes all patients undergoing surgical resection between June 1998 and December 2005 in the Department of Surgery at Peking Union Medical College Hospital. The diagnosis of PDAC, histological grading and pathologic stage were re-evaluated and/or confirmed by an independent pathologist. PanIN lesions (n = 35) and CP (n = 29) were assessed and graded in pancreatic tissues adjacent to the cancer in hematoxylin and eosin-stained slides. PDAC tissue array containing 79 independent PDAC and 3 normal pancreatic tissue samples were purchased from Cybrdi Inc., ShanXi, China.
Immunohistochemistry
Immunostaining for RNF13 was performed using the primary goat polyclonal antibody against human RNF13 (diluted 1:150) overnight after antigen retrieval in 10 mM sodium citrate buffer (pH 6.0) for 15 min at 95 ºC, followed by incubation with HRP-labeled anti-goat antibody for 1 h. Tenascin-C staining was performed after antigen retrieval of consecutive sections from samples used for RNF13 staining pretreated with 0.5 mg/mL Pronase at 37 ºC for 15 min. The sections were then incubated with mouse monoclonal anti-Tenascin-C antibody overnight at 4 ºC. Immunostaining and clinicopathologic features were evaluated microscopically by two pathologists (Jie Chen and Yun-Xiao Meng).
RNF13-specific immunoreactivity was scored by estimating the percentage of labeled tumor cells as follows: score 0, <25% positive cancer cells; score +, 25-50% positive cancer cells; score ++, 50-75% positive cancer cells; score +++, >75% positive cancer cells. Specimens were considered positive for RNF13 expression when the scores were + to +++, and were considered negative for RNF13 expression when the score was 0. Pictures were collected with MicroView MVC2000 image apparatus and software.
Statistical analysis
Data are expressed as mean±SD. Comparisons between groups were done using Welch's t test. Correlation of RNF13 immunoreactivity with clinicopathologic parameters and Tenascin-C expression were analyzed by Fisher's exact test. Differences were considered significant at P < 0.05.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
Cells were seeded in 96-well plates (n = 4) and grown for 1, 3, 5 days, followed by the MTT addition. MTT reduction into insoluble formazan was measured at 570 nm after the purple formazan crystals were dissolved in solution containing 10% SDS and 0.01 M HCl.
Matrigel invasion assay
A 10 µL aliquot of Matrigel (10 mg/mL) was spread onto a 6.5-mm Transwell filter with 8 µm pores (Costar, Corning, NY). The lower chamber of the Transwell contained serum-containing (10%) media. Cells were suspended in serum-free media with 0.1% BSA (5×10 4 cells/mL), and 0.5 mL of cell suspension was added to the top chamber and incubated for 48 h. The cell suspension was aspirated, and excess Matrigel was removed from the filter using a cotton swab. The fixed filters were stained with Crystal Violet and the cells in 5 random ×40 magnification fields were counted.
Gelatin zymography
Equal numbers of cells from the MiaP2-vector, MiaP2-RNF13 WT and MiaP2-RNF13 Mutant were plated and allowed to reach confluence over 24 h, respectively. Cells were then incubated for 24 h in 1.5 mL of serum-free DMEM. Conditioned media were collected, concentrated and analyzed with 10% SDS-PAGE co-polymerized with 0.25 mg/mL of gelatin under non-reducing conditions. Gels were washed in 2.5% Triton X-100 for 30 min, and incubated in collagenase buffer (100 mmol/L Tris-HCl pH 8.0, 5 mmol/L CaCl 2 , 0.02% NaN 3 ) for 40 h at 37 ºC. Gels were stained for 30 min with 0.5% coomassie blue and then de-stained for 1 h.
